Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: There is no consensus regarding the specific genes included in the homologous recombination repair (HRR) gene panel for identifying the HRR deficiency (HRD) status and predicting the prognosis of epithelial ovarian cancer (EOC) patients.
Objective: We aimed to explore a 15-gene panel involving the HRR pathway as a predictive prognostic indicator in Chinese patients newly diagnosed with EOC.
Patients And Methods: We reviewed the previously published reports about different HRR gene panels and prespecified the 15-gene panel. The genetic testing results in a 15-gene panel from 308 EOC patients diagnosed between 2014 and 2022 from six centers were collected. The association of clinicopathologic characteristics, the use of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and progression-free survival (PFS) with 15-gene panel HRR mutations (HRRm) status was assessed.
Results: 43.2% (133/308) of patients were determined to carry 144 deleterious HRRm, among which 68.1% (98/144) were germline mutations and 32.8% (101/308) were BRCA1/2 gene lethal mutations. The hazard ratio (HR) (95% confidence interval, CI) for PFS (HRRm v HRR wild type, HRRwt) using the 15-gene panel HRRm was 0.42 (0.28-0.64) at all stages and 0.42 (0.27-0.65) at stages IIIC-IV. However, a prognostic difference was observed only between the BRCA mutation group and the HRRwt group, not between the non-BRCA HRRm group and the HRRwt group. For the subgroups of patients not using PARPis, the HR (95% CI) was 0.41 (0.24-0.68) at stages IIIC-IV.
Conclusions: This study provides evidence that 15-gene panel HRRm can predict the prognosis of EOC, of these only the BRCA1/2 mutations, not non-BRCA HRRm, contribute to prognosis prediction. Among patients without PARPis, the HRRm group presented a better PFS. This is the first study of this kind in the Chinese population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40291-024-00726-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer.
J Cancer Res Clin Oncol
December 2024
Department of Pathology, Medical College of Georgia at Augusta University, 1120 15th Street, Augusta, GA, 30912, BF-207, USA.
Article Synopsis
- Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally, highlighting the need for effective clinical markers for patient management.
- A retrospective study utilized tissue samples from CRC patients to identify a 3-gene signature (GTF3A, PKM, VEGFA) linked to overall survival across multiple cohorts, revealing its potential as a prognostic tool.
- The identification of this gene signature could lead to cost-effective personalized treatment strategies for CRC patients, suggesting further research is necessary to refine and validate these findings.
Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience.
Curr Oncol
August 2024
Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1M9, Canada.
In advanced non-squamous non-small-cell lung cancer (NSCLC), routine testing with next-generation sequencing (NGS) is recommended to identify actionable genomic alterations (AGAs). The therapeutic implications of repeated NGS testing on synchronous and metachronous tumors are unclear. Between February 2017 and October 2020, NSCLC samples from a single institution were reflex-tested using a targeted 15-gene NGS panel (TruSight Tumor 15, Illumina).
View Article and Find Full Text PDFGenomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer.
Chin Med J (Engl)
September 2024
Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
Article Synopsis
- A study has identified a 15-gene panel that can predict the effectiveness of PD-1 blockade plus chemotherapy in patients with untreated advanced non-small-cell lung cancer (NSCLC), as not all patients respond well to this treatment.
- Researchers analyzed clinical and genomic data from 287 patients across various trials, discovering that alterations in the gene panel are linked to poorer treatment outcomes and survival rates.
- Combining the gene panel's predictive ability with PD-L1 expression levels improves the accuracy of predicting who will benefit from this treatment approach, highlighting the relationship between tumor biology and the immune environment.
Genetic Testing in Patients with Autoimmune Lymphoproliferative Syndrome: Experience of 802 Patients at Cincinnati Children's Hospital Medical Center.
J Clin Immunol
July 2024
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Article Synopsis
- Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder characterized by symptoms like swollen lymph nodes, spleen enlargement, low blood cell counts, and a higher risk of lymphoma, making diagnosis difficult, especially when mixed with similar immune deficiencies.
- A study at Cincinnati Children's Hospital evaluated a 15-gene next-generation sequencing (NGS) panel on 802 patients, revealing that 62 (7.7%) had a confirmed ALPS diagnosis, predominantly due to mutations in the FAS gene, and the diagnostic yield increased to 30% with certain immunological findings.
- The research identified novel genetic variants, showed the importance of family studies for managing at-risk relatives, and demonstrated that the ALPS
Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?
Mol Diagn Ther
September 2024
Department of Obstetrics and Gynecology, Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Article Synopsis
- There is currently no unified agreement on which genes are critical for a homologous recombination repair (HRR) gene panel used to identify HRR deficiency (HRD) in epithelial ovarian cancer (EOC) patients.
- The study aimed to evaluate a specific 15-gene HRR panel as a tool for predicting outcomes in newly diagnosed EOC patients in China.
- Findings revealed that 43.2% of the 308 EOC patients had harmful HRR mutations, with BRCA1/2 mutations specifically linked to better prognosis, particularly in patients not receiving PARP inhibitors.